合成和评价的化合物向α7和β2子单元在尼古丁酸乙胆固醇受体的合成和评价
Karanveer Singh1, Allyson Ngo1, Oshini V Keerthisinghe1
1Preclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA.
Molecules (Basel, Switzerland)
|December 23, 2023
概括
研究人员开发了KS7,一种针对尼古丁乙胆受体 (nAChRs) 的新型化合物,涉及神经退行. 自主放射学研究显示KS7
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 尼古丁乙胆受体 (nAChRs) 在中枢神经系统功能中起着至关重要的作用.
- 包括α4β2*和α7在内的nAChR亚型与神经退行性疾病有关.
- α7β2 nAChR亚型是一个较新的点,在神经退行症中具有潜在的意义.
研究的目的:
- 开发一种新型化合物KS7,针对α7β2 nAChR亚型.
- 为了研究KS7与不同nAChR亚型的结合亲和力.
- 探索KS7作为研究神经退行性疾病的工具的潜力.
主要方法:
- 在老鼠和老鼠大脑中进行的比较性自辐射学研究.
- 通过结合Nifzetidine和ASEM的结构特征开发KS7.
- 使用放射性标记的配体 ([3H]cytisine和[125I]-α-bungarotoxin) 评估KS7的结合亲和力.
主要成果:
- 在特定的大脑区域 (thalamus,海马, subiculum) 观察到α4β2*和α7 nAChR分布的显著差异.
- KS7对 [3H] 素标记的部位 (假定α4β2* nAChR) 呈现较高的亲和力,对[125I]-α-毒素标记的部位 (假定α7 nAChR) 呈现较弱的亲和力.
- 对α7nAChR的较弱结合表明KS7可能不会与α7β2nAChR的α7亚单元结合.
结论:
- KS7显示了差异性的结合亲和力,可能准含β2的nAChRs.
- 使用放射性标记的KS7衍生物进行进一步的研究可能是必要的,以确认与α7β2 nAChR亚型的结合.
- 这些发现有助于理解神经退行症中的nAChR亚型,并开发有针对性的治疗方法.
相关概念视频
Cholinergic Receptors: Nicotinic
2.8K
Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in the permeability of cells to K+, Na+, and Ca2+, followed by depolarization and excitation. They are in the autonomic ganglia, skeletal neuromuscular junction, CNS, and adrenal medulla.
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
2.8K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
982
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
982
Cholinergic Receptors: Muscarinic
2.3K
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine.
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
2.3K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.2K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.2K
Cholinergic Neurons: Neurotransmission
2.9K
Cholinergic neurotransmission involves the synthesis and the release of acetylcholine (ACh) in order to transmit nerve impulses across the synapse. The process begins with the synthesis of acetyl CoA, a precursor for ACh, from ATP, acetate, and coenzyme A in the mitochondria. Choline, another vital precursor, is transported inside the neuron through choline transporters, including high-affinity choline transporter CHT1, low-affinity choline transporter CTL1, and lower-affinity choline...
2.9K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.1K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.1K


